Reformulating a Better Fat Trap – New Approach prevents Orlistat’s bowel-related side effects
A weight loss pill has been likened to finding the Holy Grail, as the discovery of such a magical pill, can reduce the risk of a host of killer illnesses including heart disease, cancer and diabetes. One obesity drug, Orlistat, marketed by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter) is as close as scientist have come to such a pill. It is the only FDA-approved OTC weight loss drug. Since it is not a stimulant, it has no negative effects on the central nervous system.
Orlistat is the best-selling weight loss drug of all time but use is limited by so-called “socially unacceptable bowel-related side effects” as the drug can cause gas with oily discharge as well as frequent or loose stools. That’s all about to change thanks to M Pharmaceutical.
M Pharmaceutical has developed a novel formulation of Orlistat using their patented protected Chelatexx technology (patent protected in the US through 2030). The key is a sequential release dual compartment gelatin capsule or “Sequential Capsule.” Called the C-103 project, M Pharma’s drug is a patented, proprietary combination of orlistat, simethicone and activated charcoal, which is designed to maintain the efficacy of orlistat while minimizing its bowel-related side effects.
The capsule allows in the release of the three separate ingredients in a designed sequence while the capsule travels the digestive tract in order to gain the most effective result.
How effective? The C-103 reduces the urgency and other problems that Orlistat can cause by 98% – that’s almost complete elimination (forgive the pun).
Three pilot studies found that C-103 was over 97% effective in eliminating the GI adverse events associated with orlistat. This finding is consistent with the first and second of the three pilot study findings announced on August 11th and August 25th 2016 respectively, which both found C-103 was over 98% effective in eliminating the GI adverse events associated with orlistat. The results of the studies provide strong validation for the development of the C-103 reformulation of orlistat.
These findings are consistent with the first and second of the three pilot study findings announced in August, which both found C-103 was over 98% effective in eliminating the side effects.
“M Pharma’s review and assessment of these three studies fully supports our business objective to advance toward the commercialization of C-103, with the goal of helping millions of people to reach and maintain a healthy weight,” said M Pharmaceutical’s CEO Brian Keane.
For more information, log on to http://m-pharma.ca/